CVRx (CVRX) to Release Earnings on Tuesday

CVRx (NASDAQ:CVRX) is anticipated to post its Q4 2025 results before the market opens on Tuesday, February 3rd. Analysts expect CVRx to post earnings of ($0.42) per share for the quarter. Individuals can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Wednesday, February 4, 2026 at 12:00 AM ET.

CVRx (NASDAQ:CVRX) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.50) by $0.01. The business had revenue of $14.69 million for the quarter, compared to the consensus estimate of $14.16 million. CVRx had a negative return on equity of 84.45% and a negative net margin of 92.95%. On average, analysts expect CVRx to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

CVRx Stock Up 0.3%

Shares of CVRX opened at $7.33 on Tuesday. The stock has a market capitalization of $192.12 million, a price-to-earnings ratio of -3.63 and a beta of 1.31. CVRx has a 1 year low of $4.30 and a 1 year high of $17.78. The business’s 50 day simple moving average is $7.96 and its 200-day simple moving average is $8.22. The company has a debt-to-equity ratio of 1.03, a current ratio of 9.62 and a quick ratio of 8.60.

Wall Street Analyst Weigh In

CVRX has been the topic of several research reports. Cantor Fitzgerald boosted their price target on shares of CVRx from $11.00 to $13.00 and gave the stock an “overweight” rating in a research report on Thursday, November 6th. Canaccord Genuity Group lifted their price objective on shares of CVRx from $9.00 to $11.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of CVRx in a report on Monday, December 29th. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $11.40.

Insiders Place Their Bets

In related news, major shareholder & Johnson Johnson sold 52,332 shares of the firm’s stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $10.21, for a total value of $534,309.72. Following the completion of the sale, the insider directly owned 4,051,098 shares in the company, valued at $41,361,710.58. This trade represents a 1.28% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In the last 90 days, insiders sold 56,232 shares of company stock worth $573,442. Corporate insiders own 18.90% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Balyasny Asset Management L.P. raised its stake in shares of CVRx by 65.5% in the second quarter. Balyasny Asset Management L.P. now owns 674,685 shares of the company’s stock valued at $3,967,000 after acquiring an additional 267,063 shares during the period. Marshall Wace LLP boosted its stake in shares of CVRx by 238.1% during the 2nd quarter. Marshall Wace LLP now owns 350,080 shares of the company’s stock worth $2,058,000 after purchasing an additional 246,548 shares during the period. Bank of America Corp DE boosted its stake in shares of CVRx by 102.6% during the 3rd quarter. Bank of America Corp DE now owns 180,425 shares of the company’s stock worth $1,456,000 after purchasing an additional 91,376 shares during the period. UBS Group AG grew its holdings in CVRx by 71.7% during the 3rd quarter. UBS Group AG now owns 151,323 shares of the company’s stock valued at $1,221,000 after purchasing an additional 63,179 shares during the last quarter. Finally, Wexford Capital LP bought a new position in CVRx during the 3rd quarter valued at about $372,000. Institutional investors own 75.27% of the company’s stock.

CVRx Company Profile

CVRx, Inc is a clinical-stage medical device company focused on developing a neuromodulation platform therapy for patients with cardiovascular disease. The company’s flagship product, the Barostim™ system, delivers targeted electrical stimulation to the carotid baroreceptors with the goal of modulating the body’s natural blood pressure control mechanisms. This minimally invasive, implantable therapy is designed to address unmet needs in individuals suffering from hypertension and heart failure.

The Barostim system is currently being evaluated in multiple clinical trials, including studies in resistant hypertension and advanced heart failure.